Trials / Not Yet Recruiting
Not Yet RecruitingNCT07370818
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
An Open-label, Dose-finding and Randomized Active-controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of JPI-547 With Bevacizumab Maintenance Therapy in Relapsed Ovarian Cancer Patients Previously Treated With PARP Inhibitor Maintenance Therapy and Responding to Last Platinum Chemotherapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (estimated)
- Sponsor
- Onconic Therapeutics Inc. · Industry
- Sex
- Female
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JPI-547 | taking JPI-547 |
| DRUG | Bevacizumab | administration Bevacizumab |
Timeline
- Start date
- 2026-02-27
- Primary completion
- 2029-12-31
- Completion
- 2031-12-31
- First posted
- 2026-01-27
- Last updated
- 2026-01-27
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07370818. Inclusion in this directory is not an endorsement.